Enveric Biosciences (ENVB)
NASDAQ:ENVB
Want to see ENVB full AI Analyst Report?
Top Page
Enveric Biosciences
(NASDAQ:ENVB)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.50
▼(-59.68% Downside)
Action:Reiterated
Date:06/11/26
The score is primarily weighed down by weak financial performance (no revenue, sustained losses, and meaningful cash burn with a limited equity cushion). Technicals also remain bearish with the stock below key moving averages, partly offset by oversold momentum readings. Valuation provides limited support due to negative earnings, while recent governance/capital-structure actions are modestly constructive but not decisive.
Positive Factors
Debt-free balance sheet
Zero recorded debt reduces interest burden and lowers insolvency risk, giving management flexibility on capital allocation. Over a multi-month horizon this structural lack of leverage reduces fixed financial obligations, easing cash runway pressure relative to leveraged peers even as funding needs persist.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow highlights structural funding needs; absent revenue, ongoing trial and G&A spend will rapidly deplete cash. Over a 2–6 month horizon this elevates refinancing and dilution risk and can force program delays or scope cuts if markets tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero recorded debt reduces interest burden and lowers insolvency risk, giving management flexibility on capital allocation. Over a multi-month horizon this structural lack of leverage reduces fixed financial obligations, easing cash runway pressure relative to leveraged peers even as funding needs persist.
Read all positive factors
Enveric Biosciences (ENVB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.11M
Dividend YieldN/A
Average Volume (3M)781.31K
Price to Earnings (P/E)―
Beta (1Y)0.74
Revenue GrowthN/A
EPS Growth82.92%
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-27.34
Shares Outstanding3,681,884
10 Day Avg. Volume899,153
30 Day Avg. Volume781,309
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.29
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap-0.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit22.51
Enterprise Value/Ebitda0.44
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-315
Revenue Forecast (FY)$10.00M
Enveric Biosciences Business Overview & Revenue Model
Company Description
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-1...
How the Company Makes Money
null...
Enveric Biosciences Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
38
Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -157.07K | -200.86K | -337.49K | -408.03K | -435.20K | -681.61K |
| EBITDA | -8.06M | -8.57M | -9.23M | -16.85M | -19.52M | -55.74M |
| Net Income | -8.22M | -12.13M | -9.57M | ― | -18.50M | -48.98M |
Balance Sheet | ||||||
| Total Assets | 5.52M | 5.10M | 3.08M | 4.30M | 19.55M | 26.72M |
| Cash, Cash Equivalents and Short-Term Investments | 4.91M | 4.68M | 2.24M | 2.29M | 17.72M | 17.36M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 63.82K | 176.30K |
| Total Liabilities | 460.68K | 918.40K | 1.49M | 2.34M | 4.00M | 4.41M |
| Stockholders Equity | 5.06M | 4.18M | 1.59M | 1.96M | 14.67M | 22.31M |
Cash Flow | ||||||
| Free Cash Flow | -8.01M | -8.14M | -7.73M | -14.10M | -17.73M | -12.32M |
| Operating Cash Flow | -8.01M | -8.14M | -7.73M | -14.09M | -17.15M | -11.46M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 11.67K | -584.16K | 2.19M |
| Financing Cash Flow | 8.63M | 10.58M | 7.67M | -1.34M | 18.18M | 24.90M |
Enveric Biosciences Technical Analysis
Negative
3.72
Price Trends
2.64
Negative
2.53
Negative
4.82
Negative
Market Momentum
-0.31
Positive
29.18
Positive
4.69
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENVB, the sentiment is Negative. The current price of 3.72 is above the 20-day moving average (MA) of 2.03, above the 50-day MA of 2.64, and below the 200-day MA of 4.82, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 29.18 is Positive, neither overbought nor oversold. The STOCH value of 4.69 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENVB.
Enveric Biosciences Risk Analysis
Enveric Biosciences disclosed 74 risk factors in its most recent earnings report. Enveric Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Enveric Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $404.28M | -0.41 | -1028.81% | ― | ― | 61.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.39M | -0.03 | -63.03% | ― | ― | 88.07% | |
47 Neutral | $15.69M | -0.28 | -356.99% | ― | ― | -152.00% | |
42 Neutral | $6.11M | -0.28 | -262.78% | ― | ― | 82.92% | |
40 Underperform | $4.60M | -0.07 | 1937.42% | ― | ― | 27.77% |
* Healthcare Sector Average
ENVB
Enveric Biosciences
1.53
-12.99
-89.46%
BDRX
Biodexa Pharmaceuticals
3.03
-50.47
-94.34%
INDP
Indaptus Therapeutics
3.58
-5.51
-60.62%
GTBP
GT Biopharma
0.45
-2.39
-84.26%
ARTL
Artelo Biosciences
1.36
-20.23
-93.70%
Enveric Biosciences Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Enveric Biosciences Expands At-The-Market Equity Offering
Neutral
Jun 9, 2026
On June 9, 2026, Enveric Biosciences, Inc. filed a prospectus supplement to offer an additional $2.425 million of common stock under its existing at-the-market offering agreement with H.C. Wainwright Co., LLC. Prior to this filing, the company ha...
Business Operations and StrategyRegulatory Filings and Compliance
Enveric Biosciences Releases Updated Investor Presentation Materials
Neutral
Jun 9, 2026
Enveric Biosciences, Inc. announced that it has prepared new investor presentation materials that management intends to release on its website on or about June 8, 2026, and may use periodically thereafter in meetings with investors and other stake...
Business Operations and StrategyExecutive/Board ChangesShareholder MeetingsStock Split
Enveric Biosciences Shareholders Approve Directors and Reverse Split
Positive
May 29, 2026
On May 22, 2026, Enveric Biosciences’ board adopted new standard forms of restricted stock unit and restricted stock award agreements under its 2020 Long-Term Incentive Plan, setting four-year time-based vesting for RSUs with change-in-contr...
Regulatory Filings and ComplianceShareholder MeetingsStock Split
Enveric Biosciences Corrects Reverse Stock Split Proxy Disclosure
Neutral
Apr 30, 2026
On April 14, 2026, Enveric Biosciences filed its definitive proxy statement for the May 28, 2026 virtual annual meeting, seeking shareholder votes on electing six directors, an advisory say-on-pay resolution, a reverse stock split authorization in...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.